This study, called EXCLAIM, is for people with brain metastases (cancer that has spread to the brain). It's looking at how well standard systemic therapy (treatment that affects the whole body, like chemotherapy or targeted therapy) works first, and then how adding stereotactic radiosurgery (SRS, a type of focused radiation) can help control the cancer in the brain. Researchers want to see if SRS can improve how long the cancer in the brain stays under control, especially for those whose brain metastases respond well to initial systemic therapy, or for those whose brain metastases get worse. You may be eligible if you are 18 or older and have been evaluated by a team of cancer specialists.

Study design

This is a randomized Phase II interventional study, meaning participants will be assigned to different treatment groups by chance. The study plans to enroll 316 participants.

What's involved

Participants will receive systemic therapy as a standard of care option, and some may also receive stereotactic radiosurgery. The study will measure safety and side effects for about one year.

Compensation

Not stated in the trial record.

Follow-up

Safety and adverse events will be measured through study completion, which is an average of one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.